Key Drivers
- Strong margins
- High leverage
- Weaker Q4 margins
AIAI Summary
Teva has shifted from a distressed generics chassis to a conditional growth-plus-restructuring story where upside hinges on converting late‑stage specialty/biosimilar catalysts and sustaining sequential EBITDA and FCF recovery to meaningfully pay down debt and justify elevated multiples—monitor quarterly EBITDA trajectory, FCF beats (for deleveraging), and upcoming phase‑3/NDA readouts as the decisive signals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •High leverage
- •Weaker Q4 margins
Teva generates strong margins, solid ROE and free cash flow but is constrained by high leverage, elevated market multiples, sizable intangibles and recent quarter margin weakness.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Potential bounce
TEVA is in a clear downtrend over the last month, sliding from about $34.22 to $28.72 (~15–16%), with lower highs/lows signaling seller control and near-term support around $28.50 that, if broken, would reinforce bearish momentum.
Rapid ~15–16% decline from $34.22 to $28.72 over the last month
Sentiment & News
Key News Insights:
- •Pivot to specialty
- •$400M Blackstone
- •Mixed institutional
Teva is shifting from low‑margin generics into higher‑margin specialty drugs and biosimilars, highlighted by a $400M Blackstone tie‑up and rising but mixed institutional interest that's fueling investor debate amid continued generic pricing pressure.
The Blackstone deal and renewed investor focus could re‑rate TEVA if development milestones are met, but persistent generic pricing pressures and polarized sentiment raise execution risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings